An example how long granting one may take/ is from another con cious BIO company /
SYDNEY, AUSTRALIA - 15 July 2020 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 10,711,060 entitled “Antibody molecules to LAG-3 and uses thereof” by the United States Patent and Trade Mark Office. This new United States patent is directed to embodiments of LAG525, a humanised form of Immutep’s IMP701 antibody which is out-licensed to Novartis AG. In particular, the patent is directed to nucleic acid molecules that code for the LAG525 antibody, to expression vectors and host cells that comprise these nucleic acids, and to methods of producing the LAG525 antibody by culturing the host cells of the invention. The application was originally filed as a second divisional application and this grant follows the grant of the firstSYDNEY, AUSTRALIA - 15 July 2020 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the“Company”) announces the grant of patent no. 10,711,060 entitled “Antibody molecules to LAG-3 anduses thereof” by the United States Patent and Trade Mark Office.This new United States patent is directed to embodiments of LAG525, a humanised form of Immutep’sIMP701 antibody which is out-licensed to Novartis AG. In particular, the patent is directed to nucleic acidmolecules that code for the LAG525 antibody, to expression vectors and host cells that comprise thesenucleic acids, and to methods of producing the LAG525 antibody by culturing the host cells of theinvention.The application was originally filed as a second divisional application and this grant follows the grant ofthe first divisional application, as announced in March 2018. The patent is co-owned by Novartis AG andImmutep S.A.S. and will expire on 26 March 2035 (including a 13 day patent term adjustment). The patent is co-owned by Novartis AG and Immutep S.A.S. and will expire on 26 March 2035 (including a 13 day patent term adjustment).
(20min delay)